Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CSPC Pharma Out-Licenses Claudin18.2 ADC in Deal with $1 Billion in Commercial Milestones

publication date: Jul 28, 2022

CSPC Pharma out-licensed global rights (ex-China) for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment, up to $148 million in development and regulatory milestones, and as much as $1 billion in commercial milestone payments, plus royalties on net sales. CSPC is conducting a China Phase I dose escalation trial of EO-3021 in patients with gastric and pancreatic cancers, and Elevation plans to start a similar trial in the US next year. CSPC is headquartered in Shijiazhuang, Hebei Province. More details....

Stock Symbol: (HK: 01093)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital